Indications
Lubicon 24 Capsule is used for:
Irritable Bowel Syndrome with Constipation (IBS-C), Chronic idiopathic constipation, Opioid-induced Constipation (OIC) in adults with chronic non-cancer pain
Adult Dose
Oral
Chronic idiopathic constipation
Adult: 24 mcg bid daily.
Irritable Bowel Syndrome With Constipation
8 mcg twice daily.
Opioid-Induced Constipation
Treatment in patients with chronic noncancer pain
24 mcg bid daily.
Hepatic impairment
Mild: Dose adjustment not necessary
Moderate (Child-Pugh B): Chronic idiopathic or opioid-induced constipation, 16 mcg PO q12hr; irritable bowel syndrome with constipation (IBS-C), no dosage adjustment required
Severe (Child-Pugh C): Chronic idiopathic or opioid-induced constipation, 8 mcg PO q12hr; IBS-C, 8 mcg PO q24hr
Child Dose
Safety and efficacy not established
Renal Dose
Administration
Should be taken with food.
Contra Indications
History of mechanical GI obstruction.
Precautions
Safety has not been established in pregnant women. Not to be used in patients with severe diarrhoea.
Lactation: Unknown whether drug is excreted in breast milk; because lubiprostone increases fluid secretion in the intestine and intestinal motility, monitor breastfeeding infants for diarrhea
Pregnancy-Lactation
Pregnancy
Following oral administration, concentrations of lubiprostone in plasma are below the level of quantitation; however, one of the metabolites, M3, has measurable systemic concentrations
Data are not available to inform a drug associated risk of adverse developmental outcomes
Animal studies
Animal studies did not show an increase in structural malformations; however, a doses dependent increase in fetal loss was observed in pregnant guinea pigs at 0.2-6 times the MRHD
Lactation
No data are available on the presence in human milk of the refect on milk production
Animal studies
Neither lubiprostone nor its active metabolite (M3) were present in milk of lactating rats
When a drug is not present in animal milk, it is likely that the drug will not be present in human milk
If present, lubiprostone may cause diarrhea in the breastfed infant lubiprostone may cause diarrhea on effect of breastfed infants
Interactions
Side Effects
Side effects of Lubiprostone :
>10%
Nausea (29%), Headache (12%), Diarrhea (11%)
1-10%
Edema (3%), Chest discomfort (2%), Peripheral edema (1-3%), Fatigue (2%), Dizziness (3%), Flatulence (4-6%), Abdominal distress (3%), Dyspepsia (2%), Xerostomia (1%), Abdominal pain (4-8%), Loose stools (3%)
Mode of Action
Lubiprostone is a locally acting chloride channel activator that enhances a chloride-rich intestinal fluid secretion without altering sodium and potassium concentrations in the serum. Lubiprostone acts by specifically activating ClC-2, which is a normal constituent of the apical membrane of the human intestine. By increasing intestinal fluid secretion, Lubiprostone increases motility in the intestine, thereby facilitating the passage of stool and alleviating symptoms associated with chronic idiopathic constipation.
Note
Lubicon 24 24mcg Capsule generic name is Lubiprostone. Lubicon 24 24mcg Capsule is manufactured by Jenphar Bangladesh Ltd.Lubicon 24 is availble in all over Bangladesh.
Mes BD drug index information on Lubicon 24 Capsule is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.